DA acts as an agonist of the FXR and can alleviate cholestatic liver injury by activating the FXR signaling pathway, and DA has great potential for the treatment of intrahepatic cholestasis as well as a range of disorders related to lipid and glucose metabolism [18]. The gene discussed is NR1H4; the disease is intrahepatic cholestasis.